Quinupristin/dalfopristin bonding in combination with intraperitoneal antibiotics prevent infection of knitted polyester graft material in a subcutaneous rat pouch model infected with resistant Staphylococcus epidermidis

European Journal of Vascular and Endovascular Surgery

Volumn 24, Issue 3, 2002, Pages 230-234

  Ghiselli, R ^a   Giacometti, A ^b,c   Cirioni, O ^b   Mocchegiani, F ^a   Orlando, F ^a   Del Prete, M S ^b   D'Amato, G ^b   Scalise, G ^b   Saba, V ^a  

^a INRCA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c Ospedale Regionale Torrette   (Italy)

Author keywords

Antibiotics; Bacteria; Contamination; Prophylaxis; Vascular prostheses

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; LEVOFLOXACIN; ANTIINFECTIVE AGENT; OFLOXACIN; POLYESTER; QUINUPRISTIN-DALFOPRISTIN; VIRGINIAMYCIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; DACRON VASCULAR PROSTHESIS; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; GRAFT INFECTION; IN VIVO STUDY; INFECTION PREVENTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTHESIS INFECTION; RAT; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; ANIMAL; DISEASE MODEL; DRUG COMBINATION; INFECTION; INTRAPERITONEAL DRUG ADMINISTRATION; PATHOGENICITY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; DISEASE MODELS, ANIMAL; DOXYCYCLINE; DRUG THERAPY, COMBINATION; INJECTIONS, INTRAPERITONEAL; MALE; OFLOXACIN; POLYESTERS; PROSTHESIS-RELATED INFECTIONS; RATS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; VIRGINIAMYCIN;

EID: 0036716283     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1053/ejvs.2002.1713     Document Type: Article

References (32)

1. HENKE PK, BERGAMINI TM, ROSE SM, RICHARDSON JD. Current opinion in prosthetic vascular graft infection. Am Surg 1998; 64: 39-45.
2. VON EIFF C, HEILMANN C, PETERS G. New aspects in the molecular basis of polymer-associated infections due to staphylococci. Eur J Clin Microbiol Infect Dis 1999; 18: 853-856.
3. BARIE PS. antibiotic-resistant gram-positive cocci: implications for surgical practice. World J Surg 1998; 22: 118-126.
4. BERGAMINI TM, CORPUS RA JR, BRITTIAN KR, PEYTON JC, CHEADLE WG. The natural history of bacterial biofilm graft infection. J Surg Res 1994; 56: 393-396.
5. BERGAMINI TM, CORPUS RA JR, MCCURRY TM et al. Immunosuppression augments growth of graft-adherent Staphylococcus epidermidis. Arch Surg 1995; 130: 1345-1350.
6. COSTERTON JW, STEWART PS, GREENBERG EP. Bacterial biofilm: a common cause of persistent infections. Science 1999; 284: 1318-1322.
7. BERGAMINI TM, PEYTON JC, CHEADLE WG. Prophylactic antibiotics prevent bacterial biofilm graft infection. J Surg Res 1992; 52: 101-105.
8. CITAK MS, CUÉ JI, PEYTON JC, MALANGONI MA. The critical relationship of antibiotic dose and bacterial contamination in experimental infection. J Surg Res 1992; 52: 127-130.
9. MONZON M, OTEIZA C, LEIVA J, AMORENA B. Synergy of different antibiotic combinations in biofilms of Staphylococcus epidermidis. J Antimicrob Chemother 2001; 48: 793-801.
10. MARRONI M, CAO P, FIORIO M et al. Prospective, randomized, double-blind trial comparing teicoplanin and cefazolin as antibiotic prophylaxis in prosthetic vascular surgery. Eur J Clin Microbiol Infect Dis 1999; 18: 175-178.
11. MAKI DG, BOHN MJ, STOLZ SM et al. Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial. J Thorac Cardiovasc Surg 1992; 104: 1423-1434.
12. SARDELIC F, AO PY, TAYLOR DA, FLETCHER JP. Prophylaxis against Staphylococcus epidermidis vascular graft infection with rifampicin-soaked, gelatin-sealed Dacron. Cardiovasc Surg 1996; 4: 389-392.
13. CHERVU A, MOORE WS, GELABERT HA, COLBURN MD, CHVAPIL M. Prevention of graft infection by use of prostheses bonded with a rifampin collagen release system. J Vasc Surg 1991; 14: 521-524.
14. OSADA T, YAMAMURA K, FUJIMOTO K et al. Prophylaxis of local vascular graft infection with levofloxacin incorporated into albumin-sealed dacron graft. Microbiol Immunol 1999; 43: 317-321.
15. GIACOMETTI A, CIRIONI O, GHISELLI R et al. Polycationic peptides as prophylactic agents against methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis vascular graft infection. Antimicrob Agents Chemother 2000; 44: 3306-3309.
16. GHISELLI R, GIACOMETTI A, GOFFI L et al. Efficacy of rifampin- levofloxacin as a prophylactic agent in preventing Staphylococcus epidermidis graft infection. Eur J Vasc Endovasc Surg 2000, 20: 508-511.
17. COGGIA M, Goeau-BRISSONNIERE O, LEFLON V, NICOLAS MH, PECHERE JC. Experimental treatment of vascular graft infection due to Staphylococcus epidermidis by in situ replacement with a rifampin-bonded polyester graft. Ann Vasc Surg 2001; 15: 421-429.
18. GOEAU-BRISSONNIERE O, MERCIER F, NICOLAS MH et al. Treatment of vascular graft infection by in situ replacement with a rifampin-bonded gelatin-sealed Dacron graft. J Vasc Surg 1994; 19: 739-741.
19. GOEAU-BRISSONNIERE O, LEPORT C, LEBRAULT C et al. Antibiotic prophylaxis of late bacteremic vascular graft infection in a dog model. Ann Vasc Surg 1990; 4: 528-532.
20. RAAD I, ALRAHWAN A, ROLSTON K. Staphylococcus epidermidis: emerging resistance and need for alternative agents. Clin Infect Dis 1998; 26: 1182-1187.
21. BIAVASCO F, VIGNAROLI C, VARALDO PE. Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 2000; 19: 403-417.
22. HIRAMATSU K, HANAKI H, INO T et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin. J Antimicrob Chemother 1997; 40: 135-136.
23. MCMANUS AT, GOODWIN CW, PRUITT BA JR. Observations on the risk of resistance with the extended use of vancomycin. Arch Surg 1998; 133: 1207-1211.
24. JARVIS WR. Epidemiology, appropriateness, and cost of vancomycin use. Clin Infect Dis 1998; 26: 1200-1203.
25. SCHWALBE RS, STAPLETON JT, GILLIGAN PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987; 316: 927-931.
26. FUCHS PC, BARRY AL, BROWN SD. Interactions of quinupristin-dalfopristin with eight other antibiotics as measured by time-kill studies with 10 strains of Staphylococcus aureus for which quinupristin-dalfopristin alone was not bactericidal. Antimicrob Agents Chemother 2001; 45: 2662-2665.
27. SAHGAL VS, URBAN C, MARIANO N et al. Quinupristin/dalfopristin (RP 59500) therapy for vancomycin resistant Enterococcus faecium aortic graft infection: case report. Microb Drug Resist 1995; 1: 245-247.
28. CHAMBERS HF, XIANG LIU Q, LIUXIN CHOW L, HACKBARTH C. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 2742-2746.
29. CHOPRA I, HAWKEY PM, HINTON M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother 1992; 29: 245-277.
30. NATIONAL COMMITTEE for CLINICAL LABORATORY STANDARDS. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard. M7-A4. National Committee for Clinical Laboratory Standards, Wayne, PA, U.S.A.
31. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS. 1997. Performance standards for antimicrobial disk susceptibility test. Approved Standard M2-A6. National Committee for Clinical Laboratory Standards, Wayne, PA, U.S.A.
32. SIERADZKI K, VILLARI P, TOMASZ A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 1998; 42: 100-107.